Literature DB >> 32210627

Identification of Cholangiocarcinoma Associated with Hepatolithiasis via the Combination of miRNA and Ultrasound.

Wei Jiang1, Xiaofei Deng1, Ting Zhu1, Yuya Wei1, Zhen Lei1, Meimei Guo2, Jiong Yang2.   

Abstract

BACKGROUND: Identification of cholangiocarcinoma (CCA) associated with hepatolithiasis (HL) is difficult. There is no effective method to discriminate CCA associated with HL (HL-CCA) from HL currently.
OBJECTIVE: To explore the value of clinical data, ultrasonic characteristics and miRNA expression level in the identification of HL-CCA.
METHODS: Thirty-one patients with HL-CCA in Huazhong University of Science and Technology Union Shenzhen Hospital were enrolled in the observation group, while 40 patients with HL alone were included in the control group. The clinical data, ultrasonic characteristics, and miRNA expression level of the two groups were recorded and analyzed to explore the potential indicators for the identification of HL-CCA.
RESULTS: The accuracy of ultrasound in the diagnosis of HL-CCA was low (54.84%). Multivariate logistic regression analysis showed that liver abscess (P=0.021), indistinct border demarcation (P=0.015), non-homogenous echotexture (P=0.019), missed portal vein around lesion (P=0.032), miRNA-21 (P=0.018) and miRNA-221 (P=0.009) were the potential indicators for the identification of HL-CCA. The combined diagnosis based on logistic regression contained liver abscess, border demarcation, echotexture, portal vein around lesion, miRNA-21 and miRNA-221. The results showed that the accuracy of combined diagnosis identifying HL-CCA was the most accurate (AUC=0.911), which was significantly greater than the AUC of miRNA-21 or miRNA-221 individually (P<0.05), with a sensitivity and specificity of 77.42% and 97.50%, respectively.
CONCLUSION: Patients with HL-CCA show high incidence of hepatic abscess and elevated miRNA-21 and miRNA-221 expression level. The ultrasonic features are more likely to show indistinct border demarcation, non-homogenous echotexture, and missed portal vein around lesion. The combined diagnosis is more accurate in the identification of HL-CCA.
© 2020 Jiang et al.

Entities:  

Keywords:  cholangiocarcinoma; combined diagnosis; differential diagnosis; hepatolithiasis; microRNA; ultrasound

Year:  2020        PMID: 32210627      PMCID: PMC7075433          DOI: 10.2147/CMAR.S241870

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


  34 in total

1.  Intrahepatic cholangiocarcinoma in hepatolithiasis: A frequently overlooked disease.

Authors:  S M Sheen-Chen; F F Chou; H L Eng
Journal:  J Surg Oncol       Date:  1991-06       Impact factor: 3.454

2.  Analysis of new biomarkers for cholangiocarcinoma.

Authors:  Masanao Miwa; Gyokukou You; Hideaki Tanaka; Seigo Taniguchi; Takahiro Fujii; Kazuo Kamemura; Masafumi Suzaki; Takahiro Isono; Ikuo Tooyama; Masakazu Tanaka; Petcharin Srivatanakul; Chutiwan Viwatthanasittiphong; Suleeporn Sangrajrang; Thiravud Khuhaprema
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-01-21       Impact factor: 7.027

3.  miR-21 downregulates the tumor suppressor P12 CDK2AP1 and stimulates cell proliferation and invasion.

Authors:  Jun Zheng; Hui Xue; Tao Wang; Yuegui Jiang; Bei Liu; Jianhu Li; Yanpu Liu; Wei Wang; Bin Zhang; Moyi Sun
Journal:  J Cell Biochem       Date:  2011-03       Impact factor: 4.429

4.  Circulating microRNAs in plasma of patients with gastric cancers.

Authors:  M Tsujiura; D Ichikawa; S Komatsu; A Shiozaki; H Takeshita; T Kosuga; H Konishi; R Morimura; K Deguchi; H Fujiwara; K Okamoto; E Otsuji
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

5.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Authors:  Xi Chen; Yi Ba; Lijia Ma; Xing Cai; Yuan Yin; Kehui Wang; Jigang Guo; Yujing Zhang; Jiangning Chen; Xing Guo; Qibin Li; Xiaoying Li; Wenjing Wang; Yan Zhang; Jin Wang; Xueyuan Jiang; Yang Xiang; Chen Xu; Pingping Zheng; Juanbin Zhang; Ruiqiang Li; Hongjie Zhang; Xiaobin Shang; Ting Gong; Guang Ning; Jun Wang; Ke Zen; Junfeng Zhang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

6.  Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.

Authors:  Ali Tüzün Ince; Kemal Yıldız; Birol Baysal; Ahmet Danalıoğlu; Orhan Kocaman; Mukaddes Tozlu; Venkatanarayana Gangarapu; Ahu Sarbay Kemik; Ömer Uysal; Hakan Şentürk
Journal:  Turk J Gastroenterol       Date:  2014-04       Impact factor: 1.852

7.  Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival.

Authors:  Thomas Greither; Lukasz F Grochola; Andrej Udelnow; Christine Lautenschläger; Peter Würl; Helge Taubert
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

8.  miR-34 - a microRNA replacement therapy is headed to the clinic.

Authors:  Andreas G Bader
Journal:  Front Genet       Date:  2012-07-02       Impact factor: 4.599

9.  MicroRNAs and cancer: short RNAs go a long way.

Authors:  Andrea Ventura; Tyler Jacks
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

10.  Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro.

Authors:  Minhua Rong; Gang Chen; Yiwu Dang
Journal:  BMC Cancer       Date:  2013-01-16       Impact factor: 4.430

View more
  1 in total

1.  Underexpression of miR-126-3p in Patients with Cholangiocarcinoma.

Authors:  Lucas Poleto Spinola; Gabriel F Vieira; Rafael Fernandes Ferreira; Maria C J Calastri; Graciele D Tenani; Franciana L Aguiar; Ilka F Santana Ferreira Boin; Larissa B E Da Costa; Maria Fernanda Chaim Correia; Eliane M Zanovelo; Daniele C B De Souza; Rita C Martins Alves Da Silva; Renato Ferreira Da Silva; Ana Margarida Coelho Abrantes; Maria Filomena R R Botelho; Jose Guilherme L R Tralhão; Doroteia R S Souza
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.